# Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

> **NCT00118365** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 375 (actual)

## Conditions studied

- Precancerous Condition

## Interventions

- **OTHER:** placebo
- **DRUG:** eflornithine
- **DRUG:** sulindac
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00118365
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118365, "Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00118365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*